Clinical data | |
---|---|
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C33H50N4O6S |
Molar mass | 630.85 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.[1]
| |
---|---|
ACE inhibitors ("-pril") |
|
AIIRAs ("-sartan") |
|
Renin inhibitors ("-kiren") |
|
Dual ACE/NEP inhibitors |
|
Neprilysin inhibitors |
|
|
| |
---|---|
ATRTooltip Angiotensin receptor |
|
Combinations: |
|
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |